Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Albert David Ltd (ALBERTDAVD)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524075 NSE: ALBERTDAVD Pharmaceuticals & Drugs | Small Cap | Albert David Share Price
₹850.05 0.40 (0.05%)
As on 23-Sep'26 12:57
Albert David Ltd (ALBERTDAVD)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524075 NSE: ALBERTDAVD Pharmaceuticals & Drugs | Small Cap | Albert David Share Price
₹850.05 0.40 (0.05%)
As on 23-Sep'26 12:57
Key Metrics
Valuation Multiples
Market Cap
₹485 Cr.
Current Price
₹850.1
52-Week Low / High
₹581 / 925
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.8
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-3.52%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
62.24%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹5.7 Cr.
Face Value
₹10
All Time Low / High
₹3.15 / 1752.95
Check Before You Invest
Quality
Not GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Strong
Is Albert David Ltd a good quality company?
Albert David Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Albert David Ltd performance compare with that of its Peers?
Revenue growth of Albert David Ltd vs industry peers?
Albert David Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Albert David Ltd?
Promoters hold 62.24% of the Albert David Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Albert David Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 10.5% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Albert David Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 14.3% | 7.9% | 20.6% | 13.7% | 12% | 18.1% | 17.1% | 27.9% | 6.5% | 0.8% | - |
| Value Creation Index ⓘ | 0.0 | -0.4 | 0.5 | 0.0 | -0.1 | 0.3 | 0.2 | 1.0 | -0.5 | -0.9 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 295 | 290 | 317 | 321 | 247 | 314 | 342 | 362 | 346 | 334 | 364 |
| Sales YoY Gr. | - | -1.7% | 9.3% | 1.1% | -22.9% | 26.7% | 9% | 6.1% | -4.6% | -3.5% | - |
| Adj EPS ⓘ | 23.7 | 11.4 | 26 | 36.4 | 37 | 57.1 | 62.9 | 130.3 | 30.8 | 1.4 | 39.5 |
| YoY Gr. | - | -52% | 128.7% | 39.8% | 1.6% | 54.4% | 10.1% | 107.2% | -76.3% | -95.4% | - |
| BVPS (₹) ⓘ | 320.7 | 325.8 | 368.7 | 390.4 | 428.2 | 489.7 | 545.9 | 671.1 | 687.7 | 686 | 742.1 |
| Adj Net Profit ⓘ | 13.5 | 6.5 | 14.9 | 20.8 | 21.1 | 32.6 | 35.9 | 74.3 | 17.6 | 0.8 | 23 |
| Cash Flow from Ops. ⓘ | 19.9 | 30 | 31.9 | 30.3 | 36.6 | 40.4 | 10.5 | 45.5 | -28.4 | -7.7 | - |
| Debt/CF from Ops. ⓘ | 1.5 | 0.9 | 0 | 0.1 | 0 | 0.1 | 0.5 | 0.1 | -0.4 | -3.7 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 1.4% | 6.2% | -0.8% | -3.5% | ||||
| Adj EPS ⓘ | -26.9% | -48% | -71.8% | -95.4% | ||||
| BVPSⓘ | 8.8% | 9.9% | 7.9% | -0.2% | ||||
| Share Price | 10.5% | 7.5% | 4.2% | 6.4% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 8.5 | 3.5 | 7.5 | 9.6 | 9 | 12.4 | 12.1 | 21.4 | 4.5 | 0.2 | 5.5 |
| Op. Profit Mgn % ⓘ | 6.6 | 5.9 | 9.4 | 10.6 | 7.8 | 13.1 | 13.2 | 13 | 1.2 | 3 | 7.3 |
| Net Profit Mgn % ⓘ | 4.6 | 2.2 | 4.7 | 6.5 | 8.5 | 10.4 | 10.5 | 20.5 | 5.1 | 0.2 | 6.2 |
| Debt to Equity ⓘ | 0.2 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | - |
| Working Cap Days ⓘ | 194 | 212 | 193 | 190 | 227 | 183 | 201 | 201 | 232 | 259 | 201 |
| Cash Conv. Cycle ⓘ | 62 | 47 | 32 | 28 | 36 | 27 | 32 | 31 | 39 | 49 | 138 |
Valuation of Albert David - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Albert David Ltd FAQs
The current trading price of Albert David on 23-Sep-2026 12:57 is ₹850.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Albert David stood at ₹484.9 Cr
The latest P/E ratio of Albert David as of 22-Sep-2026 is 21.49.
The latest P/B ratio of Albert David as of 22-Sep-2026 is 1.14.
The 52-week high of Albert David is ₹925.0 and the 52-week low is ₹581.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Albert David is ₹364 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Albert David Ltd is a below average quality company.
The key valuation ratios of Albert David Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Albert David Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Albert David Ltd
Albert David (ADL), a prominent pharmaceutical company, is distinguished in the field of manufacturing pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs. The company is based in Kolkata, India. It belongs to the renowned industrial house of Kolkata, the “Kothari Group, India.” Equipped with cutting-edge research and development capabilities and scientific expertise, the company develops new products for the demanding global marketplace.
The company has pioneered many modern techniques in its research work and has implemented innovative ideas. Innovation is a core part of the company’s culture and guides all its strategies. The company has state-of-the-art manufacturing facilities in different parts of the country. The Kolkata manufacturing unit is a WHO-GMP-approved facility and includes a Small Volume Parenteral suite compliant with USFDA cGMP requirements. Another unit is located in Ghaziabad, near New Delhi, is an ISO 9001:2008 certified plant.
The company’s core strength lies in its vibrant team of employees and its continuous effort to bring out the best and become the best. With an extensive network of stockists across various parts of the country, the company is able to make its products available in every corner of India. The company also has a significant presence in Southeast Asia, Africa, the Middle East, Europe, the USA, and Latin America.
The company is also in strategic collaboration with academic institutes such as the Indian Institute of Chemical Biology (CSIR) and the Department of Biotechnology, University of Calcutta, for research partnerships.
Business area of the company
The company is a leading, fast growing and a professionally managed pharmaceutical company in India.
Products
Formulations
- Parenterals
- Oral / Enteral
- Topical Agents
- Vision Care
Bulk Drugs
You have 47 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
